Home    | Feature Article  |  E-ahead of Print   |  Archives   | Author Guidline   | Editorial Board

About the Journal of Applied Virology  
 Journal of Applied Virology (J. Appl. Virol. Print ISSN: 2305-5154; Online ISSN: 2306-6210) is an open access, peer- reviewed journal that considers articles on all aspects of virology, including research on viruses of human, animals, plants, bacteria and fungi. The journal also considers articles on biological products, especially for viral vaccine, etc. The journal welcomes research articles as following:
  • Virion structure and assembly,
  • Viral genome replication and regulation of gene expression,
  • Genetic diversity and evolution,
  • Viral pathogenesis and immunity,
  • Viral vaccines and antiviral agents,
  • Virus-cell interactions, cellular responses to infection,
  • Transformation and oncogenesis,
  • Gene delivery and molecular biochemistry,
  • Novel methods on virology and pre-clinical and clinical studies of anti-viral therapies.

 

Crrent Issues    Number 2  Volume 11

Articles @ Virology

Farah Nazir, Qingyu Cheng, Zunera Khalid, Tengchuan Jin

 

Abstract


 

COVID-19 is a highly contagious novel epidemic that has exploded into the world's worst health problem in modern history. Since its outbreak in late December 2019, COVID-19, a global pandemic caused by the coronavirus SARS-CoV-2, has infected millions of the world population and killed over a quarter of a million people around the globe. NGS (next-generation sequencing) is critical in various fields due to its rapid development. The present state of knowledge on SARS-CoV-2 specific T-cell receptors and their alleged role in infection and immunity leading to the target for therapeutic interventions is summarized in this article. S (Spike) glycoprotein's RBD (receptor-binding domain) is known to initiate viral fusion by attaching to its host receptor, ACE2 (angiotensin-converting enzyme-2). T-cells are critical components of the adaptive anti-viral immune response as they eliminate infected cells and aid in selecting virus-specific antibodies. When severe COVID-19 individuals and healthy controls were differentiated, peripheral T and NK cell frequencies were significantly decreased, particularly for innate-like T-cells and diverse CD8+ T-cell subsets. However, the proportions of several activated CD4+ T-cell subgroups within the T-cell compartment were elevated and clonally dilated, including Th1, Th2, and Th17-like cells. The characterization of COVID-19 TCR (T-cell receptor) groups revealed that CD8+ T-cells recognize SARS-CoV-2 epitopes, including one with immune-dominant characteristics consequent from ORF1ab. These peptides are promising candidates for the development of a COVID-19 vaccine. Numerous prophylactic methods and non-pharmacological intrusions have been used to limit disease spreading, including rigorous infection control, social distancing, and patient isolation. Nevertheless, to limit the ongoing COVID-19 pandemic and prevent its reappearance, vaccines conferring lifelong protection against the pathogenic agent SARS-CoV-2 and the emerging variants related to it must be developed.


 

Keywords

SARS-CoV-2, NGS, ACE2, T-cell receptor, Immunity, ORF
 

Full Text:

PDF


DOI: 
https://doi.org/10.21092/jav.v11i2.98
 
ABOUT THE AUTHORS

Farah Nazir:
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China.

 

Qingyu Cheng:
Laboratory of Structural Immunology, CAS Key Laboratory of innate immunity and chronic disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei, Anhui, 230027,P.R. China

 

 

Zunera Khalid:
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China.

 

 
Tengchuan Jin:
1.Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China.

2.Laboratory of Structural Immunology, CAS Key Laboratory of innate immunity and chronic disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science & Technology of China, Hefei, Anhui, 230027,P.R. China.

 3.CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai 200031, P.R. China.

 

 Number 1  Volume 11

Articles @ Virology

Vivek Darapaneni, Anusha Jaldani

 

Abstract


 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an ongoing COVID-19 pandemic that has devastated mankind. During this pandemic, it has been observed that the mortality rate in men is markedly higher than that in women. The SARS-CoV-2 membrane protein plays a decisive role in the viral life cycle. In infected people, membrane protein impedes the conversion of testosterone from active form to its inactive form via its interaction with human Aldo-keto reductase family 1 member C2 protein. This leads to the high availability of active testosterone which in turn promotes the SARS-CoV-2 entry into the host cell. In the present study, in silico analysis of interaction between membrane protein and Aldo-keto reductase family 1 member C2 protein and conservation analysis of 16,39,480 SARS-CoV-2 membrane protein revealed novel universally conserved binding site. Targeting this conserved binding site with small drug-like molecules would inhibit the interaction which leads to inhibition of SARS-CoV-2 entry into the host cell.
 

Keywords


 
SARS-CoV-2, Membrane protein, AKR1C2, Conserved, Testosterone, Binding site

 

Full Text:

PDF


DOI: 
https://doi.org/10.21092/jav.v11i1.96
 
ABOUT THE AUTHORS

Vivek Darapaneni:


Department of virology and computational biochemistry, Anvek Institute of Biomolecular Research, Visakhapatnam, India.
 

 

 

Anusha Jaldani:


Department of computational pharmacology, Anvek Institute of Biomolecular Research, Visakhapatnam, India.

 

 
 
 
 
Manuscript Tracking System
   
 

 

Submit Manuscript
  • The author should register as authour firstly by click the follows link.

 

  • Submit your article by login in the Manuscript Tracking System with your username and password.

 

 

Editorial Team

Honorary Chief Editor

Prof. Farhad Imani :ViraSource Laboratories, North Carolina,27709, USA

Chief Editor  

Dr.  Wenbo Zhang:North Carolina State Laboratory Of Public Health, Raleigh, North Carolina, USA

 Dr. Kongxin Hu:Chinese Academy of Inspection and Quarantine, China

Associate Chief Editor  

Dr. Tengchuan Jin: University of Science and Technology of China

Dr.  Tao Wang : School of Life Sciences,Tianjin University , China

Dr.  Fushun Zhang: The University of Texas Health Science Center at San Antonio, Texas, USA

Managing Director  

Dr.  Kai Wang:Institut Pasteur of Shanghai, Chinese Academy of Sciences, China

 

Abstracted/Indexed in
 

Google Scholar
    http://scholar.google.com/

  CrossRef

Index Copernicus

Directory of Open Access Journals (DOAJ)

  
NewJour
CiteFactor:

WorldCat

JournalTOC:

JournalSeek

CAB Abstracts

Baidu Scholar

Publons

JournalGuide

 

All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2012-2025 All rights reserved